Drugs / CLS-AX
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04626128 | Dec 2020 → Oct 2022 | wet macular degeneration | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05891548 | May 2023 → Aug 2024 | age-related macular degeneration | Clearside Biomedical, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLS-AX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05891548 ↗ |
| Modality | Small molecule | “injectable suspension of small molecule tyrosine kinase inhibitor (TKI)” NCT04626128 ↗ |
| Route | Other | “suprachoroidally administered CLS-AX” NCT04626128 ↗ |